American Story ! De la prohibition des opiacés (1914) à la crise des opioïdes (1995-2018) Dr Bertrand Lebeau Leibovici, CSAPA Valjean, Montfermeil (93), 2018. Du Harrison Act (1914) aux années 30 La grande vague de prohibition née dans les années 1880 dans le monde occidental aboutit aux premières conférences internationales (Shanghaï, 1909, et La Haye, 1912). Dans le même temps, les premières législations nationales apparaissent aux Etats-Unis (1914), en France (1916), en Grande-Bretagne (1920). Précédant de 5 ans la « loi sèche » (Volstead Act) de 1919 qui prohibera l’alcool durant 15 ans, le Harisson Act vise à interdire la production, l’importation et la [...]
Lire la suiteThe Anti-Inflammatory Properties of Terpenoids from Cannabis Ruth Gallily, Zhannah Yekhtin, and Lumı´r Ondrˇej Hanusˇ Cannabis and Cannabinoid Research, 3, 1, 2018, 282-290. Doi : 10.1089/can.2018.0014 Abstract : Introduction : Cannabinoids are well known to have anti-inflammatory effects in mammalians; however, the Cannabis plant also contains other compounds such as terpenoids, whose biological effects have not yet been characterized. The aim of this study was to compare the anti-inflammatory properties of terpenoids with those of cannabidiol (CBD). Materials and Methods : Essential oils prepared from three monoecious nonpsychoactive chemotypes of Cannabis were analyzed for their terpenoid content and subsequently studied pharmacologically for their anti-inflammatory properties in [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4 Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]
Lire la suiteTake medical use of cannabis seriously, say MEPs Press Releases , Plenary session , ENVI 13-02-2019 - 17:46 http://www.europarl.europa.eu/news/en/press-room/20190207IPR25221/take-medical-use-of-cannabis-seriously-say-meps The EU should stimulate innovation in medical cannabis Effective cannabis-based medicines should be covered by health insurance schemes Authorities should distinguish clearly between medical and other uses www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+20190213+TOC+DOC+XML+V0//EN&language=EN MEPs propose ways to address research gaps on medical cannabis and call on member states to seize the potential of cannabis-based medicines. In a resolution adopted on Wednesday, MEPs call on the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. The resolution urges the Commission and member [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suitePills to Pot : Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain Kevin F. Boehnke, J. Ryan Scott, Evangelos Litinas, Suzanne Sisley, David A. Williams, Daniel J. Clauw The Journal of Pain, 2019 https://www.jpain.org/article/S1526-5900(18)30735-1/fulltext DOI : https://doi.org/10.1016/j.jpain.2019.01.010 Highlights •Medical cannabis users reported substituting cannabis for pain medications. •User rationale for substitution was fewer side effects and better pain management. •Most users reported improved pain and health since using cannabis. •Intentions behind and duration of cannabis use affected substitution behavior. •Unlike previous studies, >50% of participants were women and adults >50 years old. Abstract Chronic pain is common, costly, and challenging to treat. Many [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series SHANNON S., LEWIS N., LEE H., HUGHES S. The Permanente Journal, 2019, 23 Abstract CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of [...]
Lire la suiteAdenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment Ester Aso, Víctor Fernández-Dueñas, Marc López-Cano, Jaume Taura, Masahiko Watanabe, Isidre Ferrer, Rafael Luján, Francisco Ciruela, Ester Aso Molecular Neurobiology, First Online: 04 January 2019, pp 1-10. C : Springer Nature Switzerland AG Abstract : At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can counteract the undesirable effects of the psychoactive cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) that hinder clinical development of cannabis-based therapies. Despite this attention, the mechanisms of CBD action and its interaction with Δ9-THC are still not completely elucidated. Here, by combining in vivo [...]
Lire la suiteClinical Manifestations of Cannabis Use Disorder Alan J. Budney, Jacob T. Borodovsky, and Ashley A. Knapp C Springer Nature Switzerland AG 2019 Introduction : Cannabis use disorder (CUD) or its colloquial synonym, cannabis addiction, remains controversial in that many in the general public believe that cannabis use does not pose substantial risk for harm and is not addictive in the same sense that tobacco, alcohol, cocaine, or heroin is addictive. Although assessment of people’s beliefs about addiction and harm is complicated by the lack of a consensus definition or a common understanding of addiction, the difference in perception of risk between cannabis and other [...]
Lire la suiteOral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. Frontiers in Pharmacology, 2019, 9, 1521. doi : 10.3389/fphar.2018.01521, PMID : 30687090 Objective: Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, under supervision, oral [...]
Lire la suite